About BeyondSpring Inc.
https://www.beyondspringpharma.comBeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies.
CEO
Lan Huang
Compensation Summary
(Year )
Total Compensation (Unknown At The Moment)
Industry Biotechnology
Sector Healthcare
Went public March 9, 2017
Method of going public IPO
Full time employees 40
ETFs Holding This Stock
Summary
Total 12
Showing Top 2 of 12
Ratings Snapshot
Rating : C
Discounted Cash Flow 3
Return On Equity 1
Return On Assets 4
Debt To Equity 1
Price To Earnings 1
Price To Book 1
Overall Score 2
Price Target
Target High $0
Target Low $0
Target Median $0
Target Consensus $0
Institutional Ownership
DECHENG CAPITAL MANAGEMENT III (CAYMAN), LLC
Shares:4.96M
Value:$8.28M
DECHENG CAPITAL LLC
Shares:4.29M
Value:$7.16M
BLACKROCK, INC.
Shares:639.66K
Value:$1.07M
Summary
% Of Shares Owned 27.99%
Total Number Of Holders 24
Showing Top 3 of 24
Market Cap $64.13 M
52w High $3.44
52w Low $0.98
P/E -8.79
Volume 36.90K
Outstanding Shares 40.33M
About BeyondSpring Inc.
https://www.beyondspringpharma.comBeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 | $1.77M ▼ | $-1.54M ▲ | 0% | $-0.04 ▲ | $-1.7M ▲ |
| Q2-2025 | $0 | $1.95M ▼ | $-1.81M ▼ | 0% | $-0.04 ▼ | $-1.87M ▲ |
| Q1-2025 | $0 | $2.61M ▲ | $4.48M ▲ | 0% | $0.11 ▲ | $-2.53M ▼ |
| Q4-2024 | $0 ▼ | $1.7M ▼ | $-1.73M ▲ | 0% ▲ | $0.02 ▲ | $-1.68M ▲ |
| Q2-2024 | $500K | $4.21M | $-3.63M | -726.2% | $-0.09 | $-3.64M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $12.62M ▲ | $29.48M ▼ | $49.29M ▲ | $-31.77M ▼ |
| Q2-2025 | $9.54M ▲ | $31.04M ▼ | $48.59M ▼ | $-30.22M ▼ |
| Q1-2025 | $8.53M ▲ | $37.1M ▲ | $49.77M ▲ | $-28.31M ▲ |
| Q4-2024 | $2.92M | $34.31M | $48.6M | $-32.9M |
| Q3-2024 | $2.92M | $34.31M | $48.6M | $-32.9M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-1.78M ▲ | $-4.29M ▲ | $1.62M ▼ | $279.48K ▲ | $2.94M ▼ | $-4.29M ▲ |
| Q2-2025 | $-1.81M ▲ | $-5.87M ▼ | $10.85M ▲ | $0 | $4.97M ▲ | $-5.87M ▼ |
| Q1-2025 | $-2.51M ▼ | $-4.45M ▼ | $6.3M ▲ | $0 | $-35.1M ▼ | $-4.5M ▼ |
| Q4-2024 | $0 ▲ | $0 | $0 | $0 | $0 | $0 |
| Q2-2024 | $-3.63M | $0 | $0 | $0 | $0 | $0 |
CEO
Lan Huang
Compensation Summary
(Year )
Total Compensation (Unknown At The Moment)
Industry Biotechnology
Sector Healthcare
Went public March 9, 2017
Method of going public IPO
Full time employees 40
ETFs Holding This Stock
Summary
Total 12
Showing Top 2 of 12
Ratings Snapshot
Rating : C
Discounted Cash Flow 3
Return On Equity 1
Return On Assets 4
Debt To Equity 1
Price To Earnings 1
Price To Book 1
Overall Score 2
Price Target
Target High $0
Target Low $0
Target Median $0
Target Consensus $0
Institutional Ownership
DECHENG CAPITAL MANAGEMENT III (CAYMAN), LLC
Shares:4.96M
Value:$8.28M
DECHENG CAPITAL LLC
Shares:4.29M
Value:$7.16M
BLACKROCK, INC.
Shares:639.66K
Value:$1.07M
Summary
% Of Shares Owned 27.99%
Total Number Of Holders 24
Showing Top 3 of 24